

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-24. (Canceled)

25. (Previously Presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO: 11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.

26. (Canceled)

27. (Previously Presented) An immunogen for eliciting a mutant *ras* peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide of claim 72, wherein the immunogen elicits a mutant *ras* peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response.

28.-31. (Canceled)

32. (Previously Presented) A pharmaceutical composition comprising the mutant *ras* peptide of claim 72 and a pharmaceutically acceptable carrier.

33. (Previously Presented) The pharmaceutical composition of claim 32, further comprising a biological response modifier.

34. (Previously Presented) The pharmaceutical composition of claim 32, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

35.-65. (Canceled)

66. (Previously Presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO: 11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is selected from the group

consisting of influenza peptide, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A, and poly-L-lysine.

67. (Previously Presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO: 11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is tetanus toxoid.

68. (Previously Presented) The pharmaceutical composition of claim 33, wherein the biological response modifier is interleukin 2.

69. (Canceled)

70. (Previously Presented) The pharmaceutical composition of claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF,  $\beta$ 2-microglobulin, or combinations thereof.

71. (Previously Presented) The pharmaceutical composition of claim 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

72. (Previously Presented) A mutant *ras* peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO: 11).